Company intelligence / Profile preview
Proviva Therapeutics
Boston, Massachusetts, United Statesvivabioinnovator.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Currently conducting a Phase 1 clinical trial (NCT06190886) evaluating PTX-912 in patients with locally advanced or metastatic solid tumors. The trial aims to assess safety, tolerability, PK profile, immunogenicity, and preliminary anti-tumor activity.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Antibody fusion proteinsPro-cytokine fusion protein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Proviva Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proviva Therapeutics.